Guggenheim raised target for Vaxcyte stock from USD 116.00 to USD 125.00

Vaxcyte stock was trading at EUR 59.75 at Lang & Schwarz on October 8, 2026 at 12:46 p.m. CEST, up 0.42 percent versus the prior close of EUR 59.50. On October 5, 2026, Guggenheim raised its Vaxcyte price target from USD 116.00 to USD 125.00 and retained a Buy rating, as Investing.com reported.

Guggenheim lifts its target

The analyst house also increased its estimated probability of success for VAX-31 in adults to 95.00 percent from 85.00 percent. The change followed positive results from the adult OPUS-1 Phase 3 trial, which tested VAX-31 against established pneumococcal vaccines.

Investing.com reported that VAX-31 achieved non-inferiority against all 20 serotypes compared with Prevnar 20 and against 17 of 19 serotypes compared with Capvaxive. The vaccine also cleared the predefined 0.50 lower-bound confidence threshold against both comparators across all serotypes.

Quarterly loss remains material

Vaxcyte reported diluted earnings per share of USD -1.97 for the second quarter of 2026, versus a consensus estimate of USD -2.06, according to MarketBeat. The finance data for the same quarter show an operating loss of USD 302.78 million and a net loss of USD 284.30 million, while cash and cash equivalents stood at USD 183.19 million on June 30, 2026.

The figures underline the investment profile: the clinical program is producing a stronger development signal, but Vaxcyte is still funding late-stage research from a loss-making base. The company describes VAX-31 as a 31-valent pneumococcal conjugate vaccine candidate advancing through adult Phase 3 development, according to Vaxcyte.

Stock stays below its yearly high

Vaxcyte is listed on the Nasdaq Stock Market under PCVX, as shown by FinancialContent. The primary-exchange 52-week range was USD 39.87 to USD 90.75 as of October 7, 2026, placing the latest US quote below the yearly high while the euro quotation remained close to the prior Lang & Schwarz close.

Clinical proof meets funding needs

For investors, the central tension is visible in the numbers: a USD 9.7 billion market capitalization and a USD 302.78 million quarterly operating loss sit alongside a trial result that lifted the Guggenheim success estimate by 10.00 percentage points. The target increase is a quantified sign of improved analyst confidence, while the continuing loss keeps execution, regulatory progress and financing important to the valuation.

At Lang & Schwarz, the stock was trading at EUR 59.75 on October 8, 2026 at 12:46 p.m. CEST, plus 0.42 percent against the EUR 59.50 prior close dated October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of Vaxcyte stock.

More news and analyses on Vaxcyte stock